Zhou used camrelizumab and apatinib to treat patients with advanced EGFR and ALK wild-type non–small cell lung cancer; he found that the combination regimen significantly reduced reactive capillarity to 15.6%—a rate similar to that in our study (29). This evidence concerns the gene ALK and lung cancer.